BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20709407)

  • 1. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctival and orbital lymphoma.
    Shinder R
    Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
    Sokol JA; Landau L; Lauer SA
    Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
    Nückel H; Meller D; Steuhl KP; Dührsen U
    Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
    Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
    Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
    [No Abstract]   [Full Text] [Related]  

  • 6. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional rituximab for primary iris lymphoma.
    Demirci H; Grant JS; Elner VM
    JAMA Ophthalmol; 2015 Jan; 133(1):104-5. PubMed ID: 25211092
    [No Abstract]   [Full Text] [Related]  

  • 8. [Extranodal marginal zone lymphoma of the ocular adnexa].
    Møller A; Specht L; Toft PB; Sjø LD
    Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and prognostic factors in ocular adnexal lymphoma.
    Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
    Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b.
    Lachapelle KR; Rathee R; Kratky V; Dexter DF
    Arch Ophthalmol; 2000 Feb; 118(2):284-5. PubMed ID: 10676800
    [No Abstract]   [Full Text] [Related]  

  • 13. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
    Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
    Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral conjunctival follicular lymphoma in a child.
    Wall PB; Traboulsi EI; Hsi ED; Singh AD
    J AAPOS; 2015 Apr; 19(2):183-5. PubMed ID: 25824110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).
    Son SH; Choi BO; Kim GW; Yang SW; Hong YS; Choi IB; Kim YS
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):86-91. PubMed ID: 19632068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.
    Tektonidou MG
    Lupus; 2010 Sep; 19(10):1243-5. PubMed ID: 20501524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional interferon-α for the treatment of bilateral conjunctival mucosa-associated lymphoid tissue lymphoma.
    Holds J; Buchanan A; Hanson R
    Pediatr Blood Cancer; 2012 Jul; 59(1):176-8. PubMed ID: 21793177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
    Duman BB; Sahin B; Ergin M; Guvenc B
    Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.